


Prof. Dr. Adelheid (Heidi) Cerwenka

Professor of Immunobiochemistry

Medical Faculty Mannheim, University Heidelberg

Address:

Office: Tridomus, House C, 5th Floor
Ludolf-Krehl-Strasse 13 - 17
Lab: Tridomus, House B, 3rd Floor
Ludolf-Krehl-Strasse 7 - 11
D-68167 Mannheim
Phone: +49 (0)621 / 383 -71504
Adelheid.Cerwenka@medma.uni-heidelberg.de



Professional career

- | | |
|--------------|--|
| 2019 – today | Acting Director, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University |
| 2019 – today | Vice Dean for Research, Medical Faculty Mannheim, Heidelberg University |
| 2018 – today | Member of the Habilitationsausschuss, Medical Faculty Mannheim, Heidelberg University |
| 2017 – today | Full Professor; Mannheim Institute for Innate Immunoscience (MI3) and European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University |
| 2003 – 2016 | Junior Group leader “Innate Immunity”, German Cancer Research Center, Heidelberg |
| 2001 – 2003 | Head of Laboratory, Division of Autoimmune Diseases, Novartis Research Institute Vienna, Austria |
| 1998 – 2001 | Post-doc, DNAX Research Institute and University of California, San Francisco, USA, with Prof. Lewis L. Lanier |
| 1996 – 1998 | Post-doc, University of California, San Diego, CA, USA and at the Trudeau Institute, NY, USA, with Prof. Richard W. Dutton |

Scientific degrees

- | | |
|---------|---|
| 05/2007 | Venia Legendi for Immunology, University of Heidelberg, Faculty of Medicine, Heidelberg, Germany, with Prof. Stefan Meuer |
| 09/1995 | PhD, Institute of Immunology, University of Vienna, with Prof. Walter Knapp |
| 08/1991 | Diploma in Pharmacy |

Academic education

1991 – 1995	PhD, Institute of Immunology, University of Vienna, with Prof. Walter Knapp
1986 – 1991	Diploma in Pharmacy, Institute of Immunology, University of Vienna, Austria
1986	Matura, Piaristengymnasium Krems, Austria

Honors and other activities

2020 – today	Member of the Board of Trustees, BioRN Network e.V., Heidelberg Germany
2019 – 2022	Elected member of the German Society of Immunology (DGFI) steering committee
2019 – today	Member of the Board of Trustees of Regensburger Centrum für Interventionelle Immunologie (RCI)
2018 – 2019	President of the Society of Natural Immunity (SNI)
2018 – today	Editorial board of International Journal of Cancer
2017 – today	Member of scientific advisory board of Dragonfly Therapeutics, Boston
2014 – 2017	President «elect» of the Society of Innate Immunity (SNI)
2012 – today	Coordinator of study group, NK cells, of the German Society of Immunology
2004 – 2009	Marie Curie Excellence Grant: Innate Immune Pathways; Total: 1.358.142 €
2009	Georges-Köhler Award by the German Society of Immunology, DGfI
2005	Award-Winning Research Idea at the Helmholtz-Idea-Contest: MicroRNA and Cancer
2001	Huang-Foundation-Award of the American Association of Immunologists (AAI)
1996	Erwin Schrödinger Post-doc Fellowship (2 years) by the Austrian Government
1986	“Golden Ring“ for the best graduation diploma „summa cum laude“

Publications (10 most important publications out of 115)

1. Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, Bühler L, Arnold A, Correia MP, Winkler M, Koch PS, Sexl V, Höfer T, **Cerwenka A**. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1 α Unleashes NK Cell Activity. *Immunity* 2020, Jun 16;52(6):1075-1087.e8. doi: 10.1016/j.immuni.2020.05.001. Epub 2020 May 22.
2. **Stojanovic A, Cerwenka A**. Checkpoint inhibition: NK cells enter the scene. *Nat Immunol.* 2018 Jul;19(7):650-652. doi: 10.1038/s41590-018-0142-y.
3. Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski LO, Lorenz HM, Brors B, **Cerwenka A**. Distinct human circulating NKp30⁺Fc ϵ R1 γ ⁺CD8⁺ T cell population exhibiting high natural killer-like antitumor potential. *Proc Natl Acad Sci U S A.* 2018 Jun 26;115(26):E5980-E5989. doi: 10.1073/pnas.1720564115. Epub 2018 Jun 12.
4. **Cerwenka A**, Lanier LL. Natural killers join the fight against cancer. *Science.* 2018 Mar 30;359(6383):1460-1461. doi: 10.1126/science.aat2184.

5. Pahl JHW, Koch J, Gotz JJ, Arnold A, Reusch U, Gantke T, Rajkovic E, Treder MS, **Cerwenka A**. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. *Cancer Immunol Res*. 2018 May;6(5):517-527. doi: 10.1158/2326-6066.CIR-17-0550. Epub 2018 Mar 7.
6. Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, **Cerwenka A**. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. *J Hepatol*. 2018 Mar;68(3):421-430. doi: 10.1016/j.jhep.2017.10.021. Epub 2017 Nov 1.
7. **Cerwenka A**, Lanier LL, NK cell memory in viral infection, inflammation and cancer, *Nature Immunology Reviews* 2016; Feb;16(2):112-23. doi: 10.1038/nri.2015.9.
8. Rölle A, Pollmann J, Ewen E, Halenius A, Hengel H, **Cerwenka A**. IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion in HCMV infection, *J. Clin. Invest*. 2014 Nov 10. pii: 77440. doi: 10.1172/JCI77440.
9. Ni J, Miller M, Stojanovic A, Garbi N, **Cerwenka A**. Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors. *J Exp Med* 2012; 209(13):2351-2365.
10. **Cerwenka A**, Bakker ABH, McClanahan T, Wagner J, Wu J, Phillips JH and Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. *Immunity*, 2000, 12: 721-727.